PathAI Launches AI-Based Measurement of Metabolic Dysfunction-Associated Steatohepatitis (AIM-MASH) on AISight IMS
PathAI Launches AI-Based Measurement of Metabolic Dysfunction-Associated Steatohepatitis (AIM-MASH) on AISight IMS
Key Takeaways (TLDR)
PathAI's AIM-MASH on AISight increases reproducibility and scalability for pathologists, providing an advantage in making high-quality, reproducible MASH assessments.
AIM-MASH uses AI-based measurement tools to support the analysis of MASH CRN MASLD activity score component grades and fibrosis staging.
AIM-MASH on AISight aims to make the world a better place by providing digital and AI tools to assist pathologists in making precise and reproducible assessments at scale.
AIM-MASH provides advanced AI-based measurement to support the analysis of MASH CRN MASLD activity score component grades and fibrosis staging.
Why it Matters
This news matters as it introduces a groundbreaking AI-based measurement tool, AIM-MASH, to support pathologists in making high-quality, reproducible MASH assessments. The launch of AIM-MASH on AISight IMS addresses a crucial gap in pathology labs, providing digital and AI tools to assist pathologists in making precise and reproducible assessments at scale, ultimately impacting the accuracy and efficiency of MASH evaluations.
Summary
PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, has launched its AIM-MASH1 product on the AISightⓇ1 Image Management System (IMS). This product provides advanced AI-based measurement (AIM) to support the analysis of MASH Clinical Research Network (CRN) MASLD Activity Score (MAS) component grades and fibrosis staging, aiming to increase the reproducibility and scalability of pathologists' assessments and management of MASH cases. PathAI's AIM-MASH AI-based measurement tools have been utilized in over 20 presentations and publications, demonstrating their effectiveness in assisting pathologists with MASH CRN scoring in clinical trials. The addition of AIM-MASH broadens the set of tools available through AISight to assist pathologists in making reproducible and efficient assessments of MASH.
This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is PathAI Launches AI-Based Measurement of Metabolic Dysfunction-Associated Steatohepatitis (AIM-MASH) on AISight IMS.